Evolving Treatment Strategies in Small Cell Lung Cancer
EP. 1: Importance of Early Referral and Diagnosis in Small-Cell Lung Cancer
ByTaofeek K. Owonikoko, MD, PhD,Anne Chiang, MD, PhD, Yale Cancer Center,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic Expert oncologists provide an overview of the landscape surrounding small-cell lung cancer and highlight the importance of early referral and diagnosis for overall patient outcomes.
EP. 2: Impact of Disease Staging on Prognosis and Treatment in SCLC
ByTaofeek K. Owonikoko, MD, PhD,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic Panel experts review disease staging for limited and extensive stage small-cell lung cancer and discuss the impact of staging on treatment selection.
EP. 3: Evolving Role of Biomarkers in SCLC
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic Faculty discuss the evolving role of molecular markers in small-cell lung cancer and the need for future research to identify improved biomarkers for targeted treatment options.
EP. 4: Patient Scenario 1: Newly Diagnosed ES-SCLC With Presence of Hepatic and Brain Metastases
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic A panel of expert oncologists present the case of a 68-year-old man with newly diagnosed, extensive stage small-cell lung cancer and brain metastases, who is treated with carboplatin, etoposide, and durvalumab, and provide their initial impressions.
EP. 5: Expert Insights on First-line Treatment Strategies in SCLC
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic An overview of first-line treatment options in SCLC with expert insights on important considerations in guiding treatment selection.
EP. 6: CASPIAN: Long-Term Follow-up Data and Potential Predictors for Treatment Outcomes
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic Expert oncologists discuss long-term data updates from the CASPIAN trial and the associated implications on clinical practice.
EP. 7: Combination Therapy Approaches With Chemotherapy and Immunotherapy in ES-SCLC
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic Panel experts discuss strategies aimed at preventing and managing potential adverse events with first-line combination therapy approaches in extensive stage small-cell lung cancer.
EP. 8: ADRIATIC Trial and Investigational Treatment Approaches for Limited-Stage SCLC
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic Faculty discuss potential treatment approaches for limited stage small-cell lung cancer currently under investigation in the ADRIATIC and other ongoing trials.
EP. 9: Patient Scenario 2: 1L Management of ES-SCLC Positive for Synaptophysin With a Ki-67 Score of 90%
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic Expert oncologists present the case of a 45-year-old woman with synaptophysin-positive, extensive-stage small-cell lung cancer with a Ki-67 score of 90%, who is treated with carboplatin, etoposide, and atezolizumab in the first-line setting, and provide their initial impressions.
EP. 10: Real World Data for Combination Strategies With Chemotherapy and Immunotherapy in ES-SCLC
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic Faculty discuss real world data for treatment approaches using chemotherapy in combination with immunotherapy in extensive-stage small-cell lung cancer.
EP. 11: Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic A panel of expert oncologists present the case of a 78-year-old woman who is treated with lurbinectedin following disease progress on first-line carboplatin, etoposide, and atezolizumab.
EP. 12: Evolving Treatment Strategies for SCLC in the Second-Line Setting and Beyond
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic Panel experts discuss evolving treatment options for small-cell lung cancer in the second-line setting and beyond.
EP. 13: LAGOON and IMFORTE Trials: Data Updates and Expert Insights
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic A review of the LAGOON and IMFORTE trials with expert insights regarding the potential clinical implications of current and future study findings.
EP. 14: 2L Dosing Considerations and Management Strategies for SCLC
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic Expert oncologists discuss important dosing considerations and treatment management strategies for lurbinectedin and other second-line therapy approaches in small-cell lung cancer.
EP. 15: Novel Treatment Approaches for SCLC and Future Perspectives
ByTaofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Jacob Sands, MD, Dana-Farber Cancer Institute,Konstantinos Leventakos, MD, PhD Mayo Clinic A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.
